Image-guided surgery for improved patient care and fewer complications.
Fluoptics imaging systems highlight features like the exact locations of the parathyroid glands or tissue vascularization during procedures, making it a valuable tool for surgeons.
FLUOBEAM® LX — Courtesy of FLUOPTICS© — Grenoble, France
Surgeons conventionally rely on diagnostic imaging done in advance to prepare for their procedures. Fluoptics provides them with additional real-time information invisible to the naked eye: its cameras detect contrast media circulating in the vascular or lymphatic systems or accumulating in a lymph node or vessel.
This allows surgeons to operate with even greater precision, for far more effective procedures and a vastly reduced risk of damage to healthy tissues. Fluoptics technologies were developed and validated by clinicians across the globe and are currently sold in more than 20 countries.
Fluoptics is the result of more than 10 years of research in CEA laboratories. Today the startup is a world leader in fluorescence imaging for thyroid surgery. It is also active in breast reconstruction surgery. Acquired in 2022 by the Swedish company Getinge, Fluoptics possesses a portfolio of 20 patents, including ten CEA patents for which it has exclusive licenses.
Key figure: 500
Since its inception in 2009, Fluoptics has commissioned more than 500 imaging systems
Key markets:
- Thyroid surgery
- Reconstructive surgery
- Lymphatic surgery
Technology:
- Fluorescence imaging
- Detection of contrast media through biological tissues
- Images as accurate as X-ray
Year founded: 2009
Originating institute: CEA-Leti